Rain Therapeutics most cancers drug reveals promise in part 2 trial

Rain Therapeutics (NASDAQ:RAIN) stated its drug milademetan confirmed response and antitumor exercise in preliminary information from a part 2 basket trial.

The part 2 research, dubbed MANTRA-2, is evaluating milademetan (RAIN-32) monotherapy in sufferers with superior or metastatic stable tumors refractory or illiberal to standard-of-care remedy and which exhibit wild-type p53 and a prespecified minimal MDM2 gene copy quantity.

As of the Oct. 26, 17 sufferers have been enrolled, of which 15 have been dosed with milademetan.

The corporate stated two unconfirmed partial responses (PRs) have been seen with tumor regression of 34% and 30% (pancreatic and lung most cancers, respectively). Nevertheless, the affected person with lung most cancers died on account of COVID-19.

Two sufferers confirmed promising exercise with tumor regression of 29% and 27% (biliary tract and breast most cancers, respectively) and are persevering with remedy.

Rain added that anti-tumor impact of milademetan in closely pretreated, refractory sufferers, with a median of 4 prior therapies was additionally seen.

“Remedy with milademetan led to tumor regression in sufferers beforehand handled with a large number of therapies throughout a spread of cancers. We sit up for increasing this dataset because the trial continues to enroll,” stated Rain Founder and CEO Avanish Vellanki.

Security profile was in keeping with what was seen in a part 1 trial of the drug, in line with the corporate.